Difference between revisions of "Thyroid cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "http://www.esmo.org/" to "https://www.esmo.org/")
 
(7 intermediate revisions by 2 users not shown)
Line 19: Line 19:
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
 
=Guidelines=
 
=Guidelines=
−
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.'''
+
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
 
==[https://www.thyroid.org/ ATA]==
 
==[https://www.thyroid.org/ ATA]==
 
*'''2015:''' Guidelines on the management of thyroid nodules and differentiated thyroid cancer [https://pubmed.ncbi.nlm.nih.gov/28114862/ PubMed]
 
*'''2015:''' Guidelines on the management of thyroid nodules and differentiated thyroid cancer [https://pubmed.ncbi.nlm.nih.gov/28114862/ PubMed]
 
*'''2015:''' Guidelines for the management of medullary thyroid carcinoma [https://pubmed.ncbi.nlm.nih.gov/27118126/ PubMed]
 
*'''2015:''' Guidelines for the management of medullary thyroid carcinoma [https://pubmed.ncbi.nlm.nih.gov/27118126/ PubMed]
 
*'''2012:''' Guidelines for management of patients with anaplastic thyroid cancer [https://pubmed.ncbi.nlm.nih.gov/23130564/ PubMed]
 
*'''2012:''' Guidelines for management of patients with anaplastic thyroid cancer [https://pubmed.ncbi.nlm.nih.gov/23130564/ PubMed]
−
==[http://www.esmo.org/ ESMO]==
+
==[https://www.esmo.org/ ESMO]==
 
*'''2019:''' Filetti et al. [https://doi.org/10.1093/annonc/mdz400 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/31549998 PubMed]
 
*'''2019:''' Filetti et al. [https://doi.org/10.1093/annonc/mdz400 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/31549998 PubMed]
 
**'''2012:''' Pacini et al. [https://doi.org/10.1093/annonc/mds230 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997443/ PubMed]
 
**'''2012:''' Pacini et al. [https://doi.org/10.1093/annonc/mds230 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/22997443/ PubMed]
 
**'''2010:''' Pacini et al. [https://doi.org/10.1093/annonc/mdq190 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555084/ PubMed]
 
**'''2010:''' Pacini et al. [https://doi.org/10.1093/annonc/mdq190 Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://pubmed.ncbi.nlm.nih.gov/20555084/ PubMed]
  
−
==[https://www.nccn.org/ NCCN]==
+
==NCCN==
−
*[https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf NCCN Guidelines - Thyroid Carcinoma]
+
*[https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470 NCCN Guidelines - Thyroid Carcinoma]
−
 
+
**'''2015:''' Haddad et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4986600/ Anaplastic Thyroid Carcinoma, Version 2.2015] [https://pubmed.ncbi.nlm.nih.gov/26358798/ PubMed]
−
*'''2015:''' Haddad et al. [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc4986600/ Anaplastic Thyroid Carcinoma, Version 2.2015] [https://pubmed.ncbi.nlm.nih.gov/26358798/ PubMed]
+
**'''2014:''' Tuttle et al. [https://doi.org/10.6004/jnccn.2014.0169 Thyroid Carcinoma, Version 2.2014] [https://pubmed.ncbi.nlm.nih.gov/25505208/ PubMed]
−
*'''2014:''' Tuttle et al. [https://doi.org/10.6004/jnccn.2014.0169 Thyroid Carcinoma, Version 2.2014] [https://pubmed.ncbi.nlm.nih.gov/25505208/ PubMed]
+
**'''2010:''' Tuttle et al. [https://doi.org/10.6004/Jnccn.2010.0093 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/21081783/ PubMed]
−
*'''2010:''' Tuttle et al. [https://doi.org/10.6004/Jnccn.2010.0093 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/21081783/ PubMed]
+
**'''2007:''' Sherman et al. [https://doi.org/10.6004/Jnccn.2007.0052 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/17623612/ PubMed]
−
*'''2007:''' Sherman et al. [https://doi.org/10.6004/Jnccn.2007.0052 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/17623612/ PubMed]
+
**'''2005:''' Sherman et al. [https://doi.org/10.6004/Jnccn.2005.0021 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/16002006/ PubMed]
−
*'''2005:''' Sherman et al. [https://doi.org/10.6004/Jnccn.2005.0021 Thyroid carcinoma.] [https://pubmed.ncbi.nlm.nih.gov/16002006/ PubMed]
 
  
 
=Advanced or metastatic disease=
 
=Advanced or metastatic disease=
Line 42: Line 41:
 
<div class="toccolours" style="background-color:#eeeeee">
 
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:aff447|Variant=1}}===
 
===Regimen {{#subobject:aff447|Variant=1}}===
−
{| class="wikitable" style="width: 40%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
!style="width: 25%"|Study
+
!style="width: 33%"|Study
−
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859206/ Cohen et al. 2008 (A4061014)]
 
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859206/ Cohen et al. 2008 (A4061014)]
 +
|NR
 
| style="background-color:#91cf61" |Phase 2
 
| style="background-color:#91cf61" |Phase 2
 
|-
 
|-
Line 58: Line 59:
 
# '''A4061014:''' Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. [https://doi.org/10.1200/jco.2007.15.9566 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859206/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18541897/ PubMed] [https://clinicaltrials.gov/study/NCT00094055 NCT00094055]
 
# '''A4061014:''' Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. [https://doi.org/10.1200/jco.2007.15.9566 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859206/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/18541897/ PubMed] [https://clinicaltrials.gov/study/NCT00094055 NCT00094055]
 
## '''Update:''' Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. [https://doi.org/10.1007/s00280-014-2604-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236619/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25315258/ PubMed]
 
## '''Update:''' Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. [https://doi.org/10.1007/s00280-014-2604-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236619/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25315258/ PubMed]
 +
 
==Doxorubicin monotherapy {{#subobject:41edd3|Regimen=1}}==
 
==Doxorubicin monotherapy {{#subobject:41edd3|Regimen=1}}==
 
<div class="toccolours" style="background-color:#ee6b6e">
 
<div class="toccolours" style="background-color:#ee6b6e">
Line 92: Line 94:
 
<div class="toccolours" style="background-color:#b3e2cd">
 
<div class="toccolours" style="background-color:#b3e2cd">
 
====Targeted therapy====
 
====Targeted therapy====
−
*[[Sorafenib (Nexavar)]] 400 mg PO twice per day
+
*[[Sorafenib (Nexavar)]] 400 mg PO twice per day on days 1 to 28
−
'''Continued indefinitely'''
+
'''28-day cycles'''
 
</div></div>
 
</div></div>
 
===References===
 
===References===

Latest revision as of 17:53, 23 June 2024

Back to Top

Section editor
Unfilled
If you are interested in this role, please contact us at [email protected].

Note: most thyroid cancer regimens can be found on dedicated pages:

3 regimens on this page
3 variants on this page


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ATA

  • 2015: Guidelines on the management of thyroid nodules and differentiated thyroid cancer PubMed
  • 2015: Guidelines for the management of medullary thyroid carcinoma PubMed
  • 2012: Guidelines for management of patients with anaplastic thyroid cancer PubMed

ESMO

NCCN

Advanced or metastatic disease

Axitinib monotherapy

Regimen

Study Dates of enrollment Evidence
Cohen et al. 2008 (A4061014) NR Phase 2

Targeted therapy

Continued indefinitely

References

  1. A4061014: Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00094055
    1. Update: Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. Epub 2014 Oct 15. link to original article link to PMC article PubMed

Doxorubicin monotherapy

Regimen

Study Evidence
Gottlieb et al. 1974 Non-randomized

Note: This is of historic interest.

Chemotherapy

References

  1. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med. 1974 Jan 24;290(4):193-7. link to original article PubMed

Sorafenib monotherapy

Regimen

Study Evidence Efficacy
Gupta-Abramson et al. 2008 Phase 2 ORR: 23% (95% CI, 10-42)

Targeted therapy

28-day cycles

References

  1. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. Epub 2008 Jun 9. link to original article contains dosing details in manuscript link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Thyroid_cancer&oldid=86516"